Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AbbVie is conducting a Phase 1 clinical study titled ‘A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of ABBV-932 in Healthy Adult Subjects.’ The study aims to assess adverse events and how the oral drug ABBV-932 moves through the body when administered with oral Itraconazole in healthy adults. This research is significant as it explores the pharmacokinetic interactions between these two drugs, which could inform future therapeutic strategies.
Intervention/Treatment: The study tests the combination of two oral drugs: ABBV-932 and Itraconazole. ABBV-932 is the primary drug being evaluated, while Itraconazole is used to observe its effect on the pharmacokinetics of ABBV-932. Both are administered in capsule form.
Study Design: This interventional study follows a single-group model without any masking, focusing on basic science. Participants receive ABBV-932 initially, followed by a combination of ABBV-932 and Itraconazole, to study the pharmacokinetic effects.
Study Timeline: The study began on July 15, 2025, with the most recent update submitted on July 21, 2025. These dates are crucial as they mark the study’s commencement and the latest information available, indicating the study’s current recruiting status.
Market Implications: This study could influence AbbVie’s stock performance by potentially expanding its drug portfolio with ABBV-932, depending on the outcomes. Positive results may boost investor confidence, while the competitive landscape in pharmacokinetics could impact market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.